Loading patent…
AssigneesAstraZeneca UK Limited, Daiichi Sankyo Company, Limited
InventorsMatthew Simon SUNG, Jerome Thomas METTETAL, Elisabetta LEO, Yann WALLEZ, Theresa Angela PROIA
Estimating the term…
A pharmaceutical product for administration of an anti-TROP2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an anti-TROP2 antibody) is conjugated to an anti-TROP2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (II)
A pharmaceutical product comprising an anti-TROP2 antibody-drug conjugate and a PARP1 selective inhibitor for administration in combination, wherein the anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:
22-76. (canceled)
Dependencies are inferred from the claim text.